[Skip to Content]
[Skip to Content Landing]

August 2019 - July 1959

Decade

Year

Issue

July 2012, Vol 69, No. 7, Pages 809-941

Editorial

The JAMA Network Journals: New Names for the Archives Journals

Abstract Full Text
Arch Neurol. 2012;69(7):817. doi:10.1001/archneurol.2012.1927

JAMA Neurology 2013: A New Beginning

Abstract Full Text
Arch Neurol. 2012;69(7):818. doi:10.1001/archneurol.2012.1837

Cutting-edge Questions About CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids)

Abstract Full Text
Arch Neurol. 2012;69(7):819-820. doi:10.1001/archneurol.2012.1015
Original Contribution

Long-term Outcomes of CLIPPERS (Chronic Lymphocytic Inflammation With Pontine Perivascular Enhancement Responsive to Steroids) in a Consecutive Series of 12 Patients

Abstract Full Text
free access
Arch Neurol. 2012;69(7):847-855. doi:10.1001/archneurol.2012.122

To describe the disease course of chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS), Taieb and colleagues performed a nationwide study to collect clinical, magnetic resonance imaging, cerebrospinal fluid, and brain biopsy specimen characteristics of patients with CLIPPERS. Forty-two relapses among 12 patients were analyzed.

Shapes of the Trajectories of 5 Major Biomarkers of Alzheimer Disease

Abstract Full Text
free access
Arch Neurol. 2012;69(7):856-867. doi:10.1001/archneurol.2011.3405

Using longitudinal registries from the Mayo Clinic and the Alzheimer’s Disease Neuroimaging Initiative, Jack et al characterize the shape of the trajectories of Alzheimer disease biomarkers as a function of Mini-Mental State Examination score.

Contribution of Cerebrospinal Fluid Thymosin β4 Levels to the Clinical Differentiation of Creutzfeldt-Jakob Disease

Abstract Full Text
free access
Arch Neurol. 2012;69(7):868-872. doi:10.1001/archneurol.2011.3558

Using a matrix-assisted laser desorption ionization time-of-flight mass spectrometry protein profiling analysis, Le Pera et al assess thymosin ß4 specificity as relevant to the diagnosis of Creutzfeldt-Jakob disease.

Progressive Gait Deterioration in Adolescents With Dravet Syndrome

Abstract Full Text
free access
Arch Neurol. 2012;69(7):873-878. doi:10.1001/archneurol.2011.3275

Rodda et al characterize changes in gait by age in patients with Dravet syndrome.

Preservation of Neurons of the Nucleus Basalis in Subcortical Ischemic Vascular Disease

Abstract Full Text
free access
Arch Neurol. 2012;69(7):879-886. doi:10.1001/archneurol.2011.2874

Jung and colleagues investigate loss of neurons in the nucleus basalis of Meynert in patients with subcortical ischemic vascular disease (SIVD) compared with healthy controls, patients with Alzheimer disease (AD), and patients with mixed AD and SIVD.

Alterations in Brain Transition Metals in Huntington Disease: An Evolving and Intricate Story

Abstract Full Text
free access
Arch Neurol. 2012;69(7):887-893. doi:10.1001/archneurol.2011.2945

An observational study by Rosas et al was conducted to comprehensively evaluate and validate the distribution of metal deposition in the brain using advanced magnetic resonance imaging methods from the premanifest through symptomatic stages of Huntington disease.

Effect of Genetic Variation in LRRTM3 on Risk of Alzheimer Disease

Abstract Full Text
free access
Arch Neurol. 2012;69(7):894-900. doi:10.1001/archneurol.2011.2463
Objective

Objective To explore the role of leucine-rich repeat transmembrane 3 (LRRTM3) in late-onset Alzheimer disease (AD) by independent genetic epidemiologic and functional studies.

Methods

Methods First, we explored associations between LRRTM3 single-nucleotide polymorphisms and AD in the National Institute on Aging Late-Onset Alzheimer's Disease case-control data set (993 patients and 884 control subjects) and a cohort of Caribbean Hispanics (549 patients and 544 controls) using single-marker and haplotype analyses. Then we explored the effect of LRRTM3 small-hairpin RNAs on amyloid precursor protein processing.

Results

Results One single-nucleotide polymorphism in the promoter region (rs16923760; C allele: odds ratio, −0.74, P = .03), and a block of 4 single-nucleotide polymorphisms in intron 2 (rs1925608, C allele: 0.84, P = .04; rs7082306, A allele: 0.75, P = .04; rs1925609, T allele: 1.2, P = .03; and rs10997477, T allele: 0.88, P = .05) were associated with AD in the National Institute on Aging Late-Onset Alzheimer's Disease data set or the Caribbean Hispanic data set. The corresponding haplotypes were also associated with AD risk (.01< P < .05). In addition, LRRTM3 knockdown with small-hairpin RNAs caused a significant decrease in amyloid precursor protein processing (P < .05 to P < .01) compared with the scrambled small-hairpin RNA condition.

Conclusions

Conclusions These complementary findings support the notions that genetic variation in LRRTM3 is associated with AD risk and that LRRTM3 may modulate γ-secretase processing of amyloid precursor protein. Additional studies are needed to determine whether the specific alleles associated with differential risk for AD indeed confer this risk through an effect of LRRTM3 expression levels that in turn modulates amyloid precursor protein processing.

Age and Rate of Cognitive Decline in Alzheimer Disease: Implications for Clinical Trials

Abstract Full Text
free access
Arch Neurol. 2012;69(7):901-905. doi:10.1001/archneurol.2011.3758

To determine the influence of age on Alzheimer disease (AD) course in a clinical trial setting, Bernick and colleagues studied 471 subjects with mild to moderate AD assigned to the placebo arm of 3 clinical trials conducted by the Alzheimer Disease Cooperative Study group. The trials were of 18-month duration.

Clinical Pathologic Conference

Ataxia and Weakness in a Young Woman

Abstract Full Text
free access
Arch Neurol. 2012;69(7):924-927. doi:10.1001/archneurol.2012.1207
Images in Neurology

An Unusual Case of Lower Leg Weakness

Abstract Full Text
Arch Neurol. 2012;69(7):928-929. doi:10.1001/archneurol.2011.2433

Atypical Cerebral Venous Thrombosis: Magnetic Resonance Imaging and Spectroscopy Features

Abstract Full Text
Arch Neurol. 2012;69(7):930-931. doi:10.1001/archneurol.2011.2542

“Blinding” Empty Sella: Can Lumbar Puncture Be Avoided?

Abstract Full Text
Arch Neurol. 2012;69(7):932-933. doi:10.1001/archneurol.2011.2137

Eight-and-a-Half Syndrome: A Rare Pontine Neuro-ophthalmologic Syndrome

Abstract Full Text
has multimedia
Arch Neurol. 2012;69(7):934-935. doi:10.1001/archneurol.2011.2185
Research Letter

Lack of Response to Pulse Cyclophosphamide in Neuromyelitis Optica: Evaluation of 7 Patients

Abstract Full Text
free access
Arch Neurol. 2012;69(7):938-939. doi:10.1001/archneurol.2012.545
Observation

A Serine Synthesis Defect Presenting With a Charcot-Marie-Tooth–Like Polyneuropathy

Abstract Full Text
free access
Arch Neurol. 2012;69(7):908-911. doi:10.1001/archneurol.2011.1526

Méneret and associates describe a case of serine synthesis defect due to 3­phosphoglycerate dehydrogenase deficiency in an adult with prominent chronic polyneuropathy.

Exonic Deletions of FXN and Early-Onset Friedreich Ataxia

Abstract Full Text
free access
Arch Neurol. 2012;69(7):912-916. doi:10.1001/archneurol.2011.834

Anheim and coauthors describe 6 patients affected with Friedreich ataxia due to an exonic deletion mutation (FAexdel) and compare these 6 patients with FAexdel with 46 patients consecutively diagnosed with typical FA due to homozygous GAA expansion and whose small expansions were within the same range as that of the expansions of the patients with FAexdel.

The Brighter Side of Music in Dystonia

Abstract Full Text
free access has multimedia
Arch Neurol. 2012;69(7):917-919. doi:10.1001/archneurol.2012.33

Kojovic and coauthors report a 49-year-old right-handed male civil servant with genetically proven DYT1 dystonia who shows dramatic improvement in symptoms while playing the piano.

4H Syndrome With Late-Onset Growth Hormone Deficiency Caused by POLR3A Mutations

Abstract Full Text
free access
Arch Neurol. 2012;69(7):920-923. doi:10.1001/archneurol.2011.1963

Potic and coauthors report a novel clinical and genetic presentation of a 20-year old male patient with 4H syndrome, which is a recently described leukodystrophy syndrome characterized by ataxia, hypomyelination, hypodontia, and hypogonadotropic hypogonadism.

Correction

Error in Byline: in Heterogeneity of Coenzyme Q10 Deficiency: Patient Study and Literature Review

Abstract Full Text
free access
Arch Neurol. 2012;69(7):886. doi:10.1001/archneurol.2012.1271
Book Reviews

Acute and Emergent Events in Sleep Disorders

Abstract Full Text
Arch Neurol. 2012;69(7):936. doi:10.1001/archneurol.2012.732

Primary Central Nervous System Tumors: Pathogenesis and Therapy

Abstract Full Text
Arch Neurol. 2012;69(7):937. doi:10.1001/archneurol.2012.818
This Month in Archives of Neurology

This Month in Archives of Neurology

Abstract Full Text
free access
Arch Neurol. 2012;69(7):813-814. doi:10.1001/archneurol.2011.1464
Neurological Review

Plasma Amyloid-β as a Predictor of Dementia and Cognitive Decline: A Systematic Review and Meta-analysis

Abstract Full Text
free access
Arch Neurol. 2012;69(7):824-831. doi:10.1001/archneurol.2011.1841

Koyama and colleagues conducted a systematic review and meta-analysis of relevant prospective studies to determine whether plasma amyloid-ß levels may predict development of dementia, Alzheimer disease, and cognitive decline.

Clinical Trials

Antioxidants for Alzheimer Disease: A Randomized Clinical Trial With Cerebrospinal Fluid Biomarker Measures

Abstract Full Text
free access
Arch Neurol. 2012;69(7):836-841. doi:10.1001/archneurol.2012.85

In a double-blind, placebo-controlled clinical trial, Galasko et al evaluate whether antioxidant supplements presumed to target specific cellular compartments affected cerebrospinal fluid biomarkers.

From JAMA

Organization in Autism

Abstract Full Text
Arch Neurol. 2012;69(7):906-907. doi:10.1001/archneurol.2011.3596
Correspondence

IDEAL for CCSVI Research

Abstract Full Text
Arch Neurol. 2012;69(7):939-940. doi:10.1001/archneurol.2012.322

IDEAL for CCSVI Research—Reply

Abstract Full Text
Arch Neurol. 2012;69(7):939-940. doi:10.1001/archneurol.2012.325

Physical Activity and AD-Related Pathology

Abstract Full Text
Arch Neurol. 2012;69(7):940-941. doi:10.1001/archneurol.2012.507

Physical Activity and AD-Related Pathology—Reply

Abstract Full Text
Arch Neurol. 2012;69(7):940-941. doi:10.1001/archneurol.2012.510
×